You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Lexicon completed enrollment in the 542-patient Phase 3 Sonata HCM trial, with top-line results expected in the first quarter of 2027, and plans to resubmit the Zenquista NDA for type 1 diabetes in the same quarter.
Lexicon Pharmaceuticals reported revenues of $33.0 million for the nine months ended September 30, 2026, down from $44.3 million, while net loss widened to $46.8 million from $34.8 million. Cash, cash equivalents, short-term investments and restricted cash totaled $183.2 million.
Lexicon Pharmaceuticals, Inc. completed SONATA-HCM enrollment with 542 patients, substantially exceeding planned enrollment, and expects topline results in the first quarter of 2027; ZYNQUISTA NDA resubmission is also anticipated in the first quarter of 2027.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Lexicon completed enrollment (significantly over-enrolled) in its Phase 3 SONATA-HCM study of sotagliflozin in HCM, with top-line data expected in Q1 2027, and reiterated 2026 operating expense guidance of $100-$110 million; however, ZYNQUISTA NDA resubmission in type 1 diabetes has shifted to Q4 2026, described as a slight delay from prior timeline.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LXRX
this stock
Lexicon Pharmaceuticals, Inc.
|
$796.97M | +55.7% | +60.2% | — | 5.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Lexicon Pharmaceuticals reported revenues of $33.0 million for the nine months ended September 30, 2026, down from $44.3 million, while net loss widened to $46.8 million from $34.8 million. Cash, cash equivalents, short-term investments and restricted cash totaled $183.2 million.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LXRX | +0.6% | +17.8% | -13.1% | +26.1% | +55.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.0% | +18.9% | -13.6% | +26.2% | +45.0% |
